-
Blood Borne VirusesHepatitis A Virus (HAV) Hepatitis E Virus (HEV) Parvovirus B19
-
Enteric Viruses and BacteriaClostridium difficile EHEC Norovirus Rotavirus
-
Human Adenovirus, Human Herpesvirus and PolyomavirusHuman adenovirus (ADV) Cytomegalovirus (CMV) Epstein-Barr Virus (EBV) Human Herpesvirus 6A and 6B (HHV-6) Herpes Simplex Virus 1 and 2 (HSV) Varicella-Zoster Virus (VZV) BK Virus (BKV) JC Virus (JCV)
-
Respiratory Viruses, Bacteria and FungiHuman adenovirus (ADV) Enterovirus (ENV) and Rhinovirus (RHV) Human Influenza A and B and SwineFlu Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Human Metapneumovirus A and B (hMPV) Human Parainfluenza Virus 1– 4 (PIV) Respiratory Syncytial Virus A and B (RSVA and RSVB) Bordetella pertussis and Bordetella parapertussis Pneumocystis jirovecii
-
Tropical and other Viruses, Bacteria and ParasitesAHFV/KFDV CCHFV Chagas Chikungunya Dengue Ebolavirus Filovirus Lassa Virus Malaria Rift Valley Fever Trichomonas vaginalis WNV Yellow Fever Zika Virus
Transplant Associated Disease EQA Programme
-
Cytomegalovirus Drug Resistance
-
Cytomegalovirus Whole Blood
-
Epstein-Barr virus DNA
-
Epstein-Barr virus Whole Blood
-
Human Cytomegalovirus DNA
-
Human Herpes Virus 6 DNA
-
JC virus DNA
-
Torque Teno Virus
-
Toxoplasma gondii DNA
-
Transplantation
Advances in molecular diagnostics have allowed accurate pathogen assessment prior to transplant and accurate quantitative monitoring, particularly of viral activity over time, after the transplant has been performed. This in turn allows early and accurate pre-emptive intervention and antiviral drug therapy. The range of QCMD EQA schemes within this area focus on those pathogens known to play a significant clinical role in transplant medicine. The general aim of this group of EQA schemes is to assess the ability of laboratories in the detection of the selected pathogen and where appropriate quantitative estimation is also evaluated.